Vigencell inventory crashes on Korean debut, however worth stays above provide worth

© Reuters.

From Gina Lee – South Korea's Vigencell Inc. was listed on the Korean Stock Exchange on Wednesday, and while the stock fell more than 15%, its price remained above the company's asking price of KRW 52,700.

Vigencell stock was down 16.87% to KRW 61,100 ($ 52.36) by 12:54 p.m. ET (4:54 p.m. GMT). They opened at KRW 73,500 and rose to KRW 78,000 before falling to KRW 61,000.

The company's goal was to raise approximately KRW 99.4 billion ($ 85.17 million) by issuing 1.88 million shares at a price of between KRW 42,800 and KRW 52,700.

Daishin Securities Co. Ltd. and KB Securities Co. Ltd. were the financial advisors.

Vigencell was founded in 2013 and develops immuno-oncology and immunosuppressant treatments for cancer and immune diseases, among others. It is particularly focused on the early commercialization of NK T cell lymphoma treatments.

Vigencell also has three platforms, ViTier, ViMedier and ViRanger, which are used to develop the treatments.

The company plans to use the funds raised to accelerate clinical trials, commercialize its products, and expand its global market share.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, meaning that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.

Fusion Media or any other person involved in Fusion Media assumes no liability for any loss or damage that may arise from reliance on the information contained on this website, including data, prices, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.

Related Articles